EUCALIA Inc

EUCALIA Inc has a debt-to-equity ratio of 1.43, indicating a moderate reliance on debt financing, and a current ratio of 2.17, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with free cash flow of ¥3.13 billion and operating cash flow of -¥1.63 billion, indicating some volatility in cash generation. In terms of profitability, EUCALIA Inc reports a return on equity (ROE) of 13.53% and a return on assets (ROA) of 4.26%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's revenue is concentrated in its core healthcare services and equipment segment, with no significant geographic diversification disclosed. This concentration may expose the company to regional economic fluctuations and regulatory changes. EUCALIA Inc's growth trajectory is expected to remain stable, with no significant revenue growth or decline projected in the current or next fiscal year. The company's capital expenditure of -¥920.93 million suggests a focus on cost management and operational efficiency. The company faces a medium liquidity risk due to its negative net cash position after accounting for total debt. While dilution risk is currently assessed as low, the company's capital structure and potential future financing needs could impact this assessment. Recent events, including analyst estimates and recommendations, indicate a cautious outlook from the investment community. The mean price target is ¥1,335, with a median of ¥1,335, and a mean recommendation of 2.50, suggesting a neutral stance.